Endobronchial Valve System Market

Endobronchial Valve System Market

Global endobronchial valve system market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Endobronchial valves are one-way valves inserted via bronchoscopy that restrict airflow to a particular lung segment. They permit the drainage of airway secretions during the expiratory phase but restrict incoming airflow during inspiration. Endobronchial valves were originally designed as an alternative to surgery for lung volume reduction in cases of severe emphysema. They have also been used to treat bronchopleural and bronchoalveolar fistulas with persistent air leaks.

Currently, two bronchial valve systems are FDA-approved. In June 2018, the FDA granted the Zephyr Valve system breakthrough device status with expedited approval for the bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. In December 2018, the FDA approved the Spiration Valve System for adult patients with shortness of breath and hyperinflation associated with severe emphysema in regions of the lung that have evidence of low collateral ventilation. The two valve systems differ in the mechanism by which the one-way valve is created, the Zephyr a duckbill shape and the Spiration an umbrella shape.

Market Dynamics: Drivers

Rising adoption for severe emphysema

The rising adoption of endobronchial valve systems for severe emphysema is expected to drive the market over the forecast period. Endobronchial valves are synthetic devices that are deployed with bronchoscopy into ventilatory airways of the lung to control airflow. They have been investigated for use in patients who have prolonged broncho-pleural air leaks and in patients with lobar hyperinflation from severe or advanced emphysema.

An endobronchial valve permits one-way air movement. During inhalation the valve is closed, preventing airflow to the diseased area of the lung. The valve opens during exhalation to allow air and mucus to escape from the diseased area of the lung. They have been investigated for use in emphysema patients as an alternative to lung volume reduction surgery (LVRS) and lung transplantation.

For instance, the Olympus’ Spiration Valve System (SVS) is an innovative endobronchial technology that offers patients with severe emphysema a customized, minimally invasive treatment option for lung volume reduction with a favorable risk-benefit profile. In clinical trials, patients treated with the SVS experienced improved breathing, lung function and quality of life.

By an aerodynamic design, the Spiration Valve redirects air away from diseased areas of the lung to healthier tissue, all while allowing trapped air and secretions to escape naturally along the airway wall, so that patients may breathe easier. The unique design of the Spiration Valve allows for flexible valve placement in tortuous anatomies, such as airways in the upper lobe segments, independent of airway depth or the absence of a carina.

In addition, Pulmonx’s Zephyr Endobronchial Valve was granted a “breakthrough medical status” by the FDA and is indicated for bronchoscopic treatment of patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation (CV). The Zephyr Valve is an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema.

Further, the increasing prevalence of emphysema and COPD, rising FDA approvals for novel endobronchial valve systems, increasing awareness about the advantages offered by endobronchial valves and increasing advancements are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the insertion of endobronchial valves, the high cost associated with the endobronchial valves, side effects associated with the valves and unmet needs are the factors expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global endobronchial valve system market is segmented based on device shape, application, end-user and region.

The umbrella-shaped endobronchial valves segment accounted for approximately 43.5% of the endobronchial valve system market share

The umbrella-shaped endobronchial valves segment is expected to hold the largest market share over the forecast period. These valves are specially designed to resemble an umbrella and they are typically inserted into the airways of the lungs in a minimally invasive procedure. The primary purpose of these valves is to block off specific diseased portions of the lung, redirecting airflow away from damaged areas and allowing healthier lung tissue to function more efficiently.

For instance, the unique umbrella-shaped design of Olympus’s Spiration Valve System (SVS) redirects air from diseased parts of the lung to healthier parts, all while allowing trapped air and secretions to escape naturally along the airway wall, so that patients may breathe easier. With the umbrella design of the SVS valve, a patient can easily occlude bronchi and have some anchors at the distal part to avoid migration or coughing out (valves).

The umbrella-shaped endobronchial valves can be placed in specific bronchi, allowing for targeted treatment of diseased lung lobes while preserving healthier lung tissue. This selective treatment approach helps optimize lung function. The placement of endobronchial valves is typically performed using bronchoscopy, a minimally invasive procedure. This can result in reduced trauma, shorter recovery times and potentially fewer complications compared to traditional surgical interventions.

Geographical Analysis

North America accounted for approximately 41.3% of the market share

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing adoption of the endobronchial valve systems due to the rising prevalence of emphysema and COPD in the region. North America especially the United States is known for its strong presence of major players such as medical device companies like Pulmonx Corporation which majorly focusing the development of advanced endobronchial valves like the Zephyr Endobronchial Valve.

In addition, the increasing adoption of endobronchial valve systems due to the rising prevalence of emphysema and COPD also helps to drive the market in the region. For instance, according to the National Institute of Health (NIH), the prevalence of emphysema in the United States is approximately 14 million, which includes 14% white male smokers and 3% white male nonsmokers. The prevalence is slightly less for white female smokers and African Americans.

And, in the United States, COPD affects nearly 16 million adults and many more do not know they have it. More than half of those diagnosed are women. COPD is a major cause of disability, and it is the sixth leading cause of death in the United States according to the Centers for Disease Control and Prevention (CDC). Thus, this increasing prevalence of emphysema and COPD is expected to increase the demand for endobronchial valves in the region.

Competitive Landscape

The major global players in the endobronchial valve system market include Pulmonx Corporation and Olympus America among others.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global endobronchial valve system market. The management of pneumothorax is crucial in the novel COVID-19 pneumonia patients. Although chest drain insertion represents the first line of treatment, a persistent pneumothorax and air leak requiring intervention could be managed by a thoracoscopic procedure or by endobronchial valve insertion. Endobronchial valve insertion is a minimally invasive technique that provides a treatment option in patients with severe parenchymal COVID-19-related lung disease.

Market Segmentation

By Device Shape
• Umbrella-Shaped Endobronchial Valves
• Duckbill-Shaped Endobronchial Valves

By Application
• Emphysema
• Chronic Obstructive Pulmonary Disease (COPD)
• Others

By End-User
• Hospitals
• Specialty Clinics
• Academic and Research Institutes
• Ambulatory Surgical Centers
• Others

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Why Purchase the Report?
• To visualize the global endobronchial valve system market segmentation based on device shape, application, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of endobronchial valve system market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global endobronchial valve system market report would provide approximately 37 tables, 50 figures and 189 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies